Novartis and BeiGene bookended 2021 with collaborative deals. In January, Novartis licensed the China-based company’s checkpoint inhibitor, tislelizumab. On December 20, the Swiss pharma giant announced the licensing of the late-stage TIGIT inhibitor ociperlimab to bolster Novartis’ immunotherapy pipeline.
Two weeks after winning U.S. approval as a treatment for adults with Waldenstrom’s macroglobulinemia, BeiGene’s Brukinsa scored again as a treatment for adult patients with relapsed or refractory marginal zone lymphoma (MZL).
The U.S. Food and Drug Administration accepted for review a Biologics License Application (BLA) for the anti-PD-1 antibody tislelizumab as a treatment for patients with unresectable recurrent locally advanced or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic therapy.